Entry

D11025                      Drug

Name

Idursulfase beta (INN);
Idursulfase beta (genetical recombination) (JAN);
Hunterase (TN)

Formula

C2689H4051N699O793S13

Exact mass

59238.4521

Mol weight

59274.9897

Sequence

SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID QLASHSLLFQ NAFAQQAVCA
PSRVSFLTGR RPDTTRLYDF NSYWRVHAGN FSTIPQYFKE NGYVTMSVGK VFHPGISSNH
TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD GELHANLLCP VDVLDVPEGT LPDKQSTEQA
IQLLEKMKTS ASPFFLAVGY HKPHIPFRYP KEFQKLYPLE NITLAPDPEV PDGLPPVAYN
PWMDIRQRED VQALNISVPY GPIPVDFQRK IRQSYFASVS YLDTQVGRLL SALDDLQLAN
STIIAFTSDH GWALGEHGEW AKYSNFDVAT HVPLIFYVPG RTASLPEAGE KLFPYLDPFD
SASQLMEPGR QSMDLVELVS LFPTLAGLAG LQVPPRCPVP SFHVELCREG KNLLKHFRFR
DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF
NPDEFLANFS DIHAGELYFV DSDPLQDHNM YNDSQGGDLF QLLMP
(Disulfide bridge: 146-159, 397-407)

Type

Peptide

Remark

Therapeutic category:

3959

ATC code:

A16AB16

Product:

D11025<JP>

Efficacy

Lysosomal storage disease treatment, Enzyme replacement (iduronate-2-sulfatase)

Comment

Enzyme replacement therapy product
Treatment of Hunter syndrome

Target

IDS* [HSA_VAR:3423v1] [HSA:3423] [KO:K01136]

Network

N10013

Replacement of deficient IDS

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
    A16AB Enzymes
     A16AB16 Idursulfase beta
      D11025  Idursulfase beta (INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
3  Agents affecting metabolism
  39  Other agents affecting metabolism
   395  Enzyme preparations
    3959  Others
     D11025  Idursulfase beta (INN); Idursulfase beta (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
  Hydrolases (EC3)
   Sulfatases
    IDS* [HSA_VAR:3423v1]
     D11025  Idursulfase beta (INN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D11025
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11025
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
  D11025

Other DBs

CAS:	1271734-34-9

PubChem:

350078344